GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (STU:CJH) » Definitions » Capital Expenditure

CanSino Biologics (STU:CJH) Capital Expenditure : €-71.12 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

CanSino Biologics's cash flow for capital expenditures for the three months ended in Dec. 2024 was €0.00 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Dec. 2024 was €-71.12 Mil.

CanSino Biologics Capital Expenditure Historical Data

The historical data trend for CanSino Biologics's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Capital Expenditure Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Capital Expenditure
Get a 7-Day Free Trial Premium Member Only -34.04 -167.17 -145.56 -78.40 -60.03

CanSino Biologics Quarterly Data
Dec16 Dec17 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24
Capital Expenditure Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -16.52 -20.96 -17.17 -16.47 -

CanSino Biologics Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-71.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CanSino Biologics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (STU:CJH) » Definitions » Capital Expenditure
Comparable Companies
HKSE:01558 HKSE:00570 HKSE:02005 HKSE:01681 HKSE:02186 HKSE:03613 HKSE:01349 HKSE:00460 HKSE:02877 HKSE:02561 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XSWX:GALD NSE:DIVISLAB HKSE:03692 XSWX:SDZ XTAE:TEVA
Traded in Other Exchanges
CASBF:USA 06185:Hong Kong CJH:Germany 688185:China
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
Website
https://www.cansinotech.com
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing, and commercialization of vaccine products for human use. Its products are Menhycia and Menphecia; Convidecia, Convidecia Air, and XBB.1.5 Variant; Ad5-EBOV; PCV13i; PBPV; and DTcP Infant. Its geographic areas are PRC and Overseas. It generates the majority of its revenue from the PRC.

CanSino Biologics Headlines

No Headlines